Mailman School of Public Health, Columbia Universitygrid.21729.3f Irving Medical Center, New York, New York, USA.
Hackensack Meridian Health Center for Discovery and Innovation, Nutley, New Jersey, USA.
Microbiol Spectr. 2021 Dec 22;9(3):e0188221. doi: 10.1128/Spectrum.01882-21. Epub 2021 Nov 17.
Emergence of SARS-CoV-2 with high transmission and immune evasion potential, the so-called variants of concern (VOC), is a major concern. We describe the early genomic epidemiology of SARS-CoV-2 recovered from vaccinated health care professionals (HCP). Our postvaccination COVID-19 symptoms-based surveillance program among HCPs in a 17-hospital network identified all vaccinated HCPs who tested positive for COVID-19 after routine screening or after self-reporting. From 1 January 2021 to 30 April 2021, 23,687 HCPs received either mRNA-1273 or BNT162b2 mRNA vaccine. All available postvaccination SARS-CoV-2 samples and a random collection from nonvaccinated patients during the similar time frame were subjected to VOC screening and whole-genome sequencing (WGS). Sixty-two percent (23,697/37,500) of HCPs received at least one vaccine dose, with 60% (22,458) fully vaccinated. We detected 138 (0.58%, 138/23,697) COVID-19 cases, 105 among partially vaccinated and 33 (0.15%, 33/22,458) among fully vaccinated. Five partially vaccinated required hospitalization, four with supplemental oxygen. VOC screening from 16 fully vaccinated HCPs identified 6 (38%) harboring N501Y and 1 (6%) with E484K polymorphisms; percentage of concurrent nonvaccinated samples was 37% (523/1,404) and 20% (284/1,394), respectively. There was an upward trend from January to April for E484K/Q (3% to 26%) and N501Y (1% to 49%). WGS analysis from vaccinated and nonvaccinated individuals indicated highly congruent phylogenies. We did not detect an increased frequency of any receptor-binding domain (RBD)/N-terminal domain (NTD) polymorphism between groups ( > 0.05). Our results support robust protection by vaccination, particularly among recipients of both doses. Despite VOCs accounting for over 40% of SARS-CoV-2 from fully vaccinated individuals, the genomic diversity appears to proportionally represent VOCs among nonvaccinated populations. A number of highly effective vaccines have been developed and deployed to combat the COVID-19 pandemic. The emergence and epidemiological dominance of SARS-CoV-2 mutants with high transmission potential and immune evasion properties, the so-called variants of concern (VOC), continue to be a major concern. Whether these VOCs alter the efficacy of the administered vaccines is of great concern and a critical question to study. We describe the initial genomic epidemiology of SARS-CoV-2 recovered from partial/fully vaccinated health care professionals and probe specifically for VOC enrichment. Our findings support the high level of protection provided by full vaccination despite a steep increase in the prevalence of polymorphisms associated with increased transmission potential (N501Y) and immune evasion (E484K) in the nonvaccinated population. Thus, we do not find evidence of VOC enrichment among vaccinated groups. Overall, the genomic diversity of SARS-CoV-2 recovered postvaccination appears to proportionally represent the observed viral diversity within the community.
具有高传播和免疫逃逸潜力的 SARS-CoV-2 的出现,即所谓的关注变体 (VOC),是一个主要关注点。我们描述了从接种疫苗的医护人员 (HCP) 中恢复的 SARS-CoV-2 的早期基因组流行病学。我们在一个由 17 家医院组成的网络中对 HCP 进行了基于接种后 COVID-19 症状的监测计划,以识别在常规筛查或自我报告后检测出 COVID-19 呈阳性的所有接种疫苗的 HCP。从 2021 年 1 月 1 日至 2021 年 4 月 30 日,有 23,687 名 HCP 接种了 mRNA-1273 或 BNT162b2 mRNA 疫苗。所有可用的接种后 SARS-CoV-2 样本以及在类似时间框架内从未接种疫苗的患者中随机采集的样本均进行了 VOC 筛查和全基因组测序 (WGS)。62%(23,697/37,500)的 HCP 至少接种了一剂疫苗,其中 60%(22,458)完全接种了疫苗。我们检测到了 138 例(0.58%,138/23,697)COVID-19 病例,其中 105 例为部分接种疫苗者,33 例(0.15%,33/22,458)为完全接种疫苗者。5 名部分接种疫苗者需要住院治疗,其中 4 名需要补充氧气。对 16 名完全接种疫苗的 HCP 进行的 VOC 筛查发现,6 名(38%)携带 N501Y 和 1 名(6%)携带 E484K 突变;同时期未接种疫苗的样本中分别有 37%(523/1,404)和 20%(284/1,394)携带这两种突变。E484K/Q(3%至 26%)和 N501Y(1%至 49%)的比例从 1 月到 4 月呈上升趋势。对接种疫苗和未接种疫苗个体的 WGS 分析表明,进化关系高度一致。我们没有发现两组之间( > 0.05)任何受体结合域 (RBD)/N 端结构域 (NTD) 突变的频率增加。我们的结果支持疫苗接种的强大保护作用,特别是在接种两剂疫苗的人群中。尽管 VOC 占完全接种疫苗个体 SARS-CoV-2 的 40%以上,但基因组多样性似乎与未接种人群中的 VOC 成比例。已经开发和部署了多种高效疫苗来对抗 COVID-19 大流行。具有高传播潜力和免疫逃逸特性的 SARS-CoV-2 突变体的出现和流行病学优势,即所谓的关注变体 (VOC),仍然是一个主要关注点。这些 VOC 是否会改变所接种疫苗的疗效,这是一个非常关注的问题,也是一个需要研究的关键问题。我们描述了从部分/完全接种疫苗的医护人员中恢复的 SARS-CoV-2 的初始基因组流行病学,并专门研究了 VOC 富集情况。我们的研究结果支持完全接种疫苗可提供高水平的保护作用,尽管在未接种疫苗的人群中,与传播潜力增加(N501Y)和免疫逃逸(E484K)相关的突变的流行率急剧上升。因此,我们没有发现接种组中 VOC 富集的证据。总体而言,接种后恢复的 SARS-CoV-2 的基因组多样性似乎与社区内观察到的病毒多样性成比例。